title: Prostate cancer: the new evidence base for diagnosis and treatment.
abstract: Although prostate cancer (PC) has a significant mortality, there is debate regarding the utility of PC screening. This debate continues as major studies investigating the value of population-based screening have yet to be concluded. Despite this, there is increasing evidence from preliminary reports from these series, as well as numerous others relating to outcome prediction for PC, that early detection leads to improved outcomes and a decrease in the burden of metastatic disease on our healthcare system. PC is rarely symptomatic until it has metastasised to bone and because of this PSA-based screening remains the only widely available and reliable method of diagnosis for organ-confined disease. There is now compelling evidence to show that: 1. Cancers diagnosed by screening are more likely to be early stage, when most can be cured by a number of different treatment options. 2. The maximum benefits of screening are for men aged 50-70 years. Older men have a greater chance of a clinically insignificant cancer being diagnosed for which treatment is not necessary. 3. The familial risks of PC are well recognised. In particular, men with one or more first-degree relatives already diagnosed with the disease should be actively encouraged to undergo screening. 4. Modern histopathological assessment of fine core needle biopsies of the prostate allows for the likely behaviour of cancer present to be accurately predicted. Changes that mimic those of malignancy can be confidently identified, so these cases are no longer incorrectly diagnosed. These improvements mean that now most men aged 50-70 years diagnosed with PC will have clinically significant cancers that require treatment.
authors.affiliation: Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, and Department of Radiation Oncology, Wellington Hospital, New Zealand.
authors.forename: David S
authors.initials: DS
authors.lastname: Lamb
authors.forename: David
authors.initials: D
authors.lastname: Slaney
authors.forename: Robin
authors.initials: R
authors.lastname: Smart
authors.forename: John N
authors.initials: JN
authors.lastname: Nacey
authors.forename: Grant
authors.initials: G
authors.lastname: Russell
authors.forename: Belinda
authors.initials: B
authors.lastname: Scott
authors.forename: Carol A
authors.initials: CA
authors.lastname: Johnson
authors.forename: John D
authors.initials: JD
authors.lastname: Adams
authors.forename: Sandra
authors.initials: S
authors.lastname: Moran
authors.forename: Brett
authors.initials: B
authors.lastname: Delahunt
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D000368:Aged; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D010336:Pathology / Q000639:trends*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*